Literature DB >> 31348743

Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.

Zineb Hamilou1, Scott North2, Christina Canil3, Lori Wood4, Sebastien Hotte5, Srikala S Sridhar6, Denis Soulières1, Mathieu Latour7, Daniel Taussky8, Wassim Kassouf9, Normand Blais1.   

Abstract

Entities:  

Year:  2019        PMID： 31348743      PMCID： PMC7053367          DOI： 10.5489/cuaj.5946

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  34 in total

1.  KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas.

Authors:  Riley E Alexander; Antonio Lopez-Beltran; Rodolfo Montironi; Gregory T MacLennan; Kristin M Post; Sarah A Bilbo; Timothy D Jones; Wenbin Huang; Qiu Rao; Joyashree D Sen; Kari Meehan; Anita Cornwell; Leticia Miravalle; Liang Cheng
Journal:  Histopathology       Date:  2012-07-17       Impact factor: 5.087

2.  High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations.

Authors:  S Joseph Sirintrapun; Martha Ward; Jennifer Woo; Adela Cimic
Journal:  Hum Pathol       Date:  2013-10-03       Impact factor: 3.466

3.  Carcinoma of the urachus.

Authors:  A D Beck; H J Gaudin; D G Bonham
Journal:  Br J Urol       Date:  1970-10

4.  Diagnosis of urachal carcinoma by computed tomography and magnetic resonance imaging.

Authors:  S Krysiewicz
Journal:  Clin Imaging       Date:  1990-08       Impact factor: 1.605

5.  Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.

Authors:  Matthew D Galsky; Alexia Iasonos; Svetlana Mironov; Joseph Scattergood; S Machele Donat; Bernard H Bochner; Harry W Herr; Paul Russo; Mary G Boyle; Dean F Bajorin
Journal:  Urology       Date:  2007-02       Impact factor: 2.649

6.  A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  G Goss; H Hirte; W H Miller; I A J Lorimer; D Stewart; G Batist; D A E Parolin; P Hanna; S Stafford; J Friedmann; W Walsh; S Mathews; L Douglas; L K Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

7.  Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.

Authors:  Jung Yong Hong; Moon Ki Choi; Ji Eun Uhm; Min Jae Park; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Won Seog Kim; Won Ki Kang; Hyun Moo Lee; Han Yong Choi; Hoyeong Lim
Journal:  Med Oncol       Date:  2008-11-06       Impact factor: 3.064

Review 8.  Urachal adenocarcinoma: a clinician's guide for treatment.

Authors:  Arlene Siefker-Radtke
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

9.  Urachal carcinoma: a pathologic and clinical study of 46 cases.

Authors:  Jasreman Dhillon; Yu Liang; Ashish M Kamat; Arlene Siefker-Radtke; Colin P Dinney; Bogdan Czerniak; Charles C Guo
Journal:  Hum Pathol       Date:  2015-08-12       Impact factor: 3.466

10.  Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.

Authors:  Julian R Molina; J Fernando Quevedo; Alfred F Furth; Ronald L Richardson; Horst Zincke; Patrick A Burch
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860
View more
  8 in total

1.  U-shaped relationship of age at diagnosis and cancer-specific mortality in primary urachal adenocarcinoma: a cohort study.

Authors:  Dong-Dong Yu; Hui Dong; Zhi-Gang Wu; Yun-Bei Xiao; Chao-Feng Zhou; Qin-Quan Wang; Jian Cai
Journal:  Transl Androl Urol       Date:  2020-06

2.  Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma.

Authors:  Jeeban P Das; Hebert A Vargas; Soleen Ghafoor; Alvin C Goh; Gary A Ulaner
Journal:  J Nucl Med       Date:  2020-09-18       Impact factor: 10.057

3.  Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.

Authors:  Rami Mäkelä; Antti Arjonen; Ville Härmä; Nina Rintanen; Lauri Paasonen; Tobias Paprotka; Kerstin Rönsch; Teijo Kuopio; Juha Kononen; Juha K Rantala
Journal:  BMC Cancer       Date:  2020-06-23       Impact factor: 4.430

4.  Successful treatment of locally advanced urachal adenocarcinoma with peri-operative gemcitabine - cisplatin combination therapy: a case report and perspective on targeted therapies.

Authors:  Ioannis A Voutsadakis
Journal:  Cent European J Urol       Date:  2020-11-20

5.  Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients With Primary Urachal Carcinoma: A Study Based on SEER Database.

Authors:  Li Ding; Bin Xia; Yang Zhang; Zijie Liu; Junqi Wang
Journal:  Front Public Health       Date:  2022-06-02

6.  Primary urachal adenocarcinoma treated effectively with surgery and post operative chemoradiation therapy: Case Report with review of the literature.

Authors:  Fadila Kouhen; Meriem Chihabeddine; Zineb Dahbi; Imane Benali; Meriem Damou; Nejwa Benslima; Abdeljalil Haddat; Nadia Errafiy; Mohammed Mahi; Radouane Rabii
Journal:  Radiol Case Rep       Date:  2021-06-16

7.  Metastatic Urachal Carcinoma Treated With Several Different Combined Regimens: A Case Report.

Authors:  Han Zheng; Wei Song; Xiemin Feng; Hong Zhao
Journal:  Front Oncol       Date:  2021-07-16       Impact factor: 6.244

8.  Development and validation of a nomogram for predicting survival in patients with non-metastatic primary adenocarcinoma of the bladder.

Authors:  Dong-Dong Yu; Hui Dong; Wei-Kang Chen; Kun Chen; Zhi-Gang Wu; Cheng-Di Li; Jian Cai; Yun-Bei Xiao
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.